Bradley & Co Private Wealth Management’s ALX Oncology ALXO Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.07K	Hold	1,000	–	–	﹤0.01%	191
2026 Q1	$2K	Hold	1,000	–	–	﹤0.01%	185
2025 Q4	$1.13K	Hold	1,000	–	–	﹤0.01%	196
2025 Q3	$1.83K	Hold	1,000	–	–	﹤0.01%	183
2025 Q2	$415	Hold	1,000	–	–	﹤0.01%	185
2025 Q1	$623	Hold	1,000	–	–	﹤0.01%	179
2024 Q4	$1.67K	Buy	+1,000	New	+$1.54K	﹤0.01%	165
2024 Q2	$6.03K	Hold	1,000	–	–	﹤0.01%	128
2024 Q1	$11.2K	Hold	1,000	–	–	0.01%	119
2023 Q4	$14.9K	Hold	1,000	–	–	0.01%	110
2023 Q3	$4.8K	Hold	1,000	–	–	0.01%	133
2023 Q2	$7.51K	Hold	1,000	–	–	0.01%	120
2023 Q1	$4.52K	Hold	1,000	–	–	0.01%	135
2022 Q4	$11.3K	Hold	1,000	–	–	0.01%	113
2022 Q3	$10K	Hold	1,000	–	–	0.01%	123
2022 Q2	$8K	Buy	+1,000	New	+$10.9K	0.01%	138

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Bradley & Co Private Wealth Management's ALXO Position: Q2 2026 in Review

Bradley & Co Private Wealth Management held its ALX Oncology (ALXO) position steady in Q2 2026 at 1,000 shares worth $2.07K. The position accounts for ﹤0.01% of the portfolio, ranked #191.

Bradley & Co Private Wealth Management first reported a position in ALXO in Q2 2022 and has held it in 16 quarters since. The position peaked at $14.9K in Q4 2023. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Bradley & Co Private Wealth Management held 1,000 shares of ALX Oncology worth $2.07K as of Q2 2026.
Bradley & Co Private Wealth Management left its ALX Oncology share count unchanged in Q2 2026.
ALX Oncology made up ﹤0.01% of Bradley & Co Private Wealth Management's portfolio in Q2 2026, its #191 holding.
Bradley & Co Private Wealth Management first reported a position in ALX Oncology in Q2 2022 and has held it in 16 quarters since.
Bradley & Co Private Wealth Management's ALX Oncology position peaked at $14.9K in Q4 2023.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Bradley & Co Private Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.